- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03463369
A First-In-Human Study to Evaluate Safety, Tolerability, Reactogenicity, and Immunogenicity of JNJ-64300535, a DNA Vaccine, Administered by Electroporation-Mediated Intramuscular Injection, in Participants With Chronic Hepatitis B Who Are on Stable Nucleos(t)Ide Therapy and Virologically Suppressed
April 13, 2021 updated by: Janssen Sciences Ireland UC
A First-In-Human, Double-Blind, Randomized, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, Reactogenicity, and Immunogenicity of JNJ-64300535, a DNA Vaccine, Administered by Electroporation-Mediated Intramuscular Injection, in Participants With Chronic Hepatitis B Who Are on Stable Nucleos(T)Ide Therapy and Virologically Suppressed
The purpose of this study is to evaluate the safety, tolerability, and reactogenicity of escalating doses of JNJ-64300535 delivered via electroporation-mediated intramuscular injection in nucleos(t)ide analogs (NA)-treated chronic hepatitis B (CHB) participants.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
30
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Antwerp, Belgium
- ZiekenhuisNetwerk Antwerpen (ZNA) - Stuivenberg
-
Brussels, Belgium
- Université libre de Bruxelles (ULB) - Hôpital Erasme
-
Brussels, Belgium
- Universite Catholique de Louvain (UCL) - Cliniques Universitaires Saint-Luc
-
-
-
-
-
Hamburg, Germany
- IFI Hamburg
-
Leipzig, Germany
- UK Leipzig
-
Regensburg, Germany
- Universitat Regensburg
-
-
Baden-Wuerttemberg
-
Mannheim, Baden-Wuerttemberg, Germany, 68167
- Ruprecht-Karls-U Mannheim
-
-
Lower Saxony
-
Hannover, Lower Saxony, Germany, 30625
- MH Hannover
-
-
North Rhine-Westphalia
-
UK Essen, North Rhine-Westphalia, Germany, 45122
- Universitätsklinikum Essen
-
-
-
-
-
Birmingham, United Kingdom, B15 2GW
- Queen Elizabeth - Birmingham
-
London, United Kingdom, NW3 2PF
- Royal Free - London
-
London, United Kingdom, SE5 9RS
- King's College - London
-
London, United Kingdom
- Bart's Health - Blizard Inst. London
-
Manchester, United Kingdom, E1 1BB
- Pennine Acute Hospitals - Manchester
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Has chronic hepatitis B virus envelope antigen (HBeAg) negative hepatitis B virus (HBV) infection documented by a positive hepatitis B virus surface antigen (HBsAg) test and/or detectable HBV deoxyribonucleic acid (DNA) at least 6 months prior to the screening visit
- Is on a stable treatment with one of the approved oral nucleos(t)ide analogs (NA) polymerase inhibitors tenofovir alafenamide, tenofovir disoproxil fumarate, or entecavir for greater than or equal to (>=)12 months prior to screening. A history of switching between the above treatments is acceptable as long as it was not triggered by virologic failure
- Must demonstrate HBV DNA levels less than (<)60 international unit/milliliter (IU/mL) on 2 occasions separated by greater than (>)6 months (of which one can be the screening assessment).
- Has HBsAg levels at screening between 100 IU/mL and 10,000 IU/mL
- Has normal alanine aminotransferase (ALT) levels for at least 6 months prior to baseline with no documented measurement exceeding 1.25 times upper limit of normal [ULN]). Minimal requirement is documentation of two ALT results within the year prior to baseline of which one can be the screening assessment.
Exclusion Criteria:
- Presence of advanced hepatic fibrosis or cirrhosis in 1 of the assessments below done less than or equal to (<=)6 month prior to baseline: a. Metavir score 3 or 4 in a liver biopsy OR b. Fibroscan result of >9 kilopascal (kPa) OR c. Acoustic Radiation Force Impulse (ARFI) result of >=1.55 meter/second (m/s)
Clinical signs or history of liver cirrhosis or hepatic decompensation:
- Metavir score 4 in a historical biopsy OR
- ascites, esophageal varices, or hepatic encephalopathy OR
- documentation of one of the following laboratory abnormality within 12 months of screening:
i. direct (conjugated) bilirubin >1.2 times upper limit of normal (ULN) OR ii. prothrombin time (PT) >1.2 times ULN OR iii. serum albumin <3.5 gram per deciliter (g/dL)
Positive serology test at screening for any of the following:
- anti-hepatitis B surface (ant-HBs) antibodies
- HBeAg
- anti-human immunodeficiency virus (HIV)-1 or anti-HIV-2 antibodies
- anti-hepatitis A virus (HAV) immunoglobulin M (IgM) antibodies
- anti-hepatitis C virus (ant-HCV) antibodies
- anti-hepatitis D virus (anti-HDV) antibodies
- Participants with any evidence of liver disease of non-HBV etiology. This includes but is not limited to hepatitis A, C, or D virus infections (as above), drug- or alcohol-related liver disease, autoimmune hepatitis, hemochromatosis, Wilson's disease, α-1 antitrypsin deficiency, primary biliary cirrhosis, primary sclerosing cholangitis, non-alcoholic steatohepatitis or any other non-HBV liver disease considered clinically significant by the investigator
- Has a history of persistent or recurrent hyperbilirubinemia unless explained by known Gilbert's Disease
- History of blood disorders (bleeding problems or a blood clot, thalassemia major or sickle cell anemia).
- History of severe local or systemic reactions to any vaccination or a history of severe allergic reactions.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Placebo + Nucleos(t)ide Analogs (NA)
Participants will receive placebo intramuscular (IM) injection on Day 1, Week 4, and Week 12, along with standard of care NA treatment.
|
Participants will receive 1 mL (0.9 percent [%] sodium chloride [NaCl]) of placebo solution matching to JNJ-64300535 electroporation-mediated IM injection on Day 1, Week 4, and Week 12.
Participants will receive NA as a standard of care treatment.
|
Experimental: JNJ-64300535 + NA
Participants will receive JNJ-64300535 IM injection on Day 1, Week 4, and Week 12, along with standard of care NA treatment.
|
Participants will receive NA as a standard of care treatment.
Participants will receive JNJ-64300535 vaccine by electroporation-mediated IM injection on Day 1, Week 4, and Week 12.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants with Adverse Events (AEs) by Severity and Relationship to Study Treatment and Dose Level
Time Frame: Up to Week 16
|
An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
Severity of AEs will be graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events as follows: Mild = Grade 1, Moderate = Grade 2, Severe = Grade 3, Potentially life-threatening = Grade 4.
|
Up to Week 16
|
Number of Participants With Laboratory Abnormalities
Time Frame: Up to Week 16
|
Number of participants with laboratory abnormalities related to hematology, serum chemistry, coagulation, liver function tests and urinalysis will be reported.
Laboratory abnormalities will be graded according to the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events as follows: Mild = Grade 1, Moderate = Grade 2, Severe = Grade 3, Potentially life-threatening = Grade 4.
|
Up to Week 16
|
Number of Participants With Clinically Significant Changes in Vital Signs
Time Frame: Up to Week 16
|
Number of participants with clinically significant changes in the vital signs including blood pressure, pulse/heart rate, and body temperature will be reported.
|
Up to Week 16
|
Number of Participants With Clinically Significant Changes in Physical Examination (Palpation of Lymph Nodes, Height, Body Weight, and Skin Examination) Findings
Time Frame: Up to Week 16
|
Number of participants with clinically significant changes in physical examination parameters will be reported.
Full physical examination (including palpation of lymph nodes, height, body weight, and skin examination) and symptom-directed physical examination will be performed.
|
Up to Week 16
|
Number of Participants With Acute Injection Site Reactions on Day 1
Time Frame: From 0 to 2 hours post-vaccination on Day 1
|
Participants will be assessed for the acute injection site reactions.
Acute reactions means the reactions which occur within 0 to 2 hours post-vaccination.
Acute reactions will be graded as follows: Grade 0 = Normal, Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Potentially Life Threatening.
|
From 0 to 2 hours post-vaccination on Day 1
|
Number of Participants With Acute Injection Site Reactions at Week 4
Time Frame: From 0 to 2 hours post-vaccination at Week 4
|
Participants will be assessed for the acute injection site reactions.
Acute reactions means the reactions which occur within 0 to 2 hours post-vaccination.
Acute reactions will be graded as follows: Grade 0 = Normal, Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Potentially Life Threatening.
|
From 0 to 2 hours post-vaccination at Week 4
|
Number of Participants With Acute Injection Site Reactions at Week 12
Time Frame: From 0 to 2 hours post-vaccination at Week 12
|
Participants will be assessed for the acute injection site reactions.
Acute reactions means the reactions which occur within 0 to 2 hours post-vaccination.
Acute reactions will be graded as follows: Grade 0 = Normal, Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Potentially Life Threatening.
|
From 0 to 2 hours post-vaccination at Week 12
|
Number of Participants With Injection Site Reactions After Vaccination on Day 1
Time Frame: Up to 7 days post-vaccination on Day 1
|
Participants will be assessed for the Reactogenicity.
Reactogenicity means injection site reactions which occur after 7 days post- vaccination.
Severity of reactions will be graded as follows: Grade 0 = Normal, Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Potentially Life Threatening.
|
Up to 7 days post-vaccination on Day 1
|
Number of Participants With Injection Site Reactions After Vaccination on Week 4
Time Frame: Up to 7 days post-vaccination on Week 4
|
Participants will be assessed for the Reactogenicity.
Reactogenicity means injection site reactions which occur after 7 days post-vaccination.
Severity of reactions will be graded as follows: Grade 0 = Normal, Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Potentially Life Threatening.
|
Up to 7 days post-vaccination on Week 4
|
Number of Participants With Injection Site Reactions After Vaccination on Week 12
Time Frame: Up to 7 days post-vaccination on Week 12
|
Participants will be assessed for the Reactogenicity.
Reactogenicity means injection site reactions which occur after 7 days post- vaccination.
Severity of reactions will be graded as follows: Grade 0 = Normal, Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Potentially Life Threatening.
|
Up to 7 days post-vaccination on Week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With a Positive Hepatitis B Virus (HBV) Specific T Cells Response
Time Frame: Day 1, Week 2, 6, 14, 24, 48, and 60
|
Percentage of participants with a positive HBV-specific T cells response, assessed by interferon (IFN)-gamma ELISpot assay will be reported.
|
Day 1, Week 2, 6, 14, 24, 48, and 60
|
Time to Detection of HBV Specific T-Cell Responses
Time Frame: Day 1 up to Week 60
|
Time to HBV Specific T-Cell response is defined as the time interval between Day 1 (vaccination) to the date of first evidence of positive HBV Specific T-Cell response.
|
Day 1 up to Week 60
|
Percentage of CD4+ and CD8+ T-Cell Responses
Time Frame: Day 1, Week 2, 6, 14, 24, 48, and 60
|
The activation of CD4+ and CD8+ T-cell subsets and their cytokine expression patterns (expressing at least 1 interleukin [IL]-2, tumor necrosis factor-alpha [TNF-α] or IFN-γ specific to any antigen) will be determined by Intracellular Cytokine Staining (ICS).
|
Day 1, Week 2, 6, 14, 24, 48, and 60
|
Hepatitis B Antigen-Specific Cellular Immune Response
Time Frame: Day 1, Week 2, 6, 14, 24, 48, and 60
|
Magnitude of Hepatitis B antigen-specific cellular immune responses will be assessed by ICS.
|
Day 1, Week 2, 6, 14, 24, 48, and 60
|
Number of TriGrid Delivery System (TDS)-Intramuscular (IM) v2.0 Device Fault Conditions by Type
Time Frame: Day 1, Week 4 and 12
|
Number of TDS-IM v2.0 device fault conditions by type will be observed.
User reported fault conditions will be documented to enable assessment of the device reliability.
Device functions to be assessed include electrode/needle deployment, study treatment administration, and electroporation application.
|
Day 1, Week 4 and 12
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 18, 2018
Primary Completion (Actual)
March 23, 2021
Study Completion (Actual)
March 23, 2021
Study Registration Dates
First Submitted
February 28, 2018
First Submitted That Met QC Criteria
March 10, 2018
First Posted (Actual)
March 13, 2018
Study Record Updates
Last Update Posted (Actual)
April 14, 2021
Last Update Submitted That Met QC Criteria
April 13, 2021
Last Verified
April 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Liver Diseases
- Hepatitis, Viral, Human
- Hepadnaviridae Infections
- DNA Virus Infections
- Enterovirus Infections
- Picornaviridae Infections
- Hepatitis, Chronic
- Hepatitis B
- Hepatitis
- Hepatitis A
- Hepatitis B, Chronic
Other Study ID Numbers
- 64300535HPB1001 (Other Identifier: Janssen Sciences Ireland UC)
- 2017-000147-41 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatitis B, Chronic
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...Gilead SciencesNot yet recruiting
-
Tongji HospitalGilead SciencesRecruiting
-
Jiangsu HengRui Medicine Co., Ltd.Unknown
-
Changhai HospitalCompleted
-
Tongji HospitalChia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownChronic Hepatitis b
-
Zhongshan Hospital Xiamen UniversityUnknownHealthy | Chronic Hepatitis B InfectionChina
-
Brii Biosciences LimitedVir Biotechnology, Inc.Active, not recruitingChronic Hepatitis B Virus InfectionSingapore, Thailand, Australia, China, Korea, Republic of
-
Nanfang Hospital of Southern Medical UniversityRecruiting
-
IlDong Pharmaceutical Co LtdRecruitingChronic Hepatitis bKorea, Republic of
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States